Dioxidin(Dioxidin) - 在研适应症：脓皮症，感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Hydroxymethylquinoxalindioxyde

靶点-

作用机制-

治疗领域

皮肤和肌肉骨骼疾病感染

在研适应症

脓皮症感染

非在研适应症-

原研机构

Valenta Pharmaceuticals JSC

在研机构

Valenta Pharmaceuticals JSC

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Dioxidin 相关的临床试验

NCT05561816 / Completed临床3期

Opened, Multicenter, Randomized, in Parallel Groups Comparative Study to Assess Efficacy and Safety of Dioxidin®, Solution for Topical and External Application 0.025% (Valenta Farm, Russia) and Miramistin®, Solution for Topical Application 0.01% (Infamed K LLC, Russia) in Treatment of Superficial Pyoderma

The study is aimed to:
evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma,
evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

开始日期2022-07-19

申办/合作机构

Valenta Pharmaceuticals JSC

NCT05505097 / Completed临床1期

Open Randomized Comparative Crossover Study of the Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

The study aimed for:
To study the safety of the drug Dioxidin, solution for topical and external use;
To determine the concentrations of the active substance of the studied drugs Dioxidin, solution for topical and external use, and Dioxidin, solution for infusion and external use in discrete time intervals;
To study pharmacokinetics of the drug Dioxidin, solution for topical and external application;
To determine the absolute bioavailability of the drug Dioxidine, solution for topical and external use.

开始日期2022-05-04

申办/合作机构

Valenta Pharmaceuticals JSC

100 项与 Dioxidin 相关的临床结果

登录后查看更多信息

100 项与 Dioxidin 相关的转化医学

登录后查看更多信息

100 项与 Dioxidin 相关的专利（医药）

登录后查看更多信息

23

项与 Dioxidin 相关的文献（医药）

2013-01-01·Khirurgiia

[Modern opportunities of abdominal sanation during the generalized purulent peritonitis].

Article

作者: Pervova, O V ; Cherdantsev, D V ; Diatlov, V Iu ; Pozdniakov, A A ; Shapkina, V A

Results of the treatment of generalized purulent peritonitis in 30 patients are presented. Based on the analysis of the performance of integrated assessment scales severity of the condition, the dynamics of change of bacterial contamination and microbiological landscape, and analysis of morbidity and mortality proved the effectiveness of intraperitoneal administration of the solution of dioxidin in patients with generalized purulent peritonitis.

2013-01-01·Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]

[Dioxidin: antimicrobial activity and prospects of its clinical use at present].

Article

作者: Kostiuk, G V ; Terekhova, L P ; Pkhakadze, T Ia ; Aleksandrova, I A ; Bogomolova, N S ; Rusanova, E V ; Blatun, L A ; Terent'ev, A A ; Piopov, D A ; Anuchina, N M

In vitro activity of dioxidin against pathogens of nosocomial infections and its cytotoxicity were estimated. The study involved 300 isolates from patients with nosocomial infections. The MICs of dioxidin were determined with the method of serial dilutions in broth. The dioxidin cytotoxicity was investigated with the MTI assay to assign the cell culture viability. In concentrations of 2 to 1024 meg/mi dioxidin was active against 279/300 (93%) strains. The drug inhibited the growth of all the gramnegative isolates. The highest activitywas observed against Enterobacteriaceae vs. nonfermenting gramnegative bacteria: the median, minimum and maximum MICs of dioxidin were 12 (4-32) and 32 (16-64) mcg/ml respectively. The dioxidin activity against gramnegative bacteria and fungi was lower. The MIC of dioxidin for 7/70 (10%) staphylococcal isolates, 9/28 (32%) enterococcal isolates and all the Candida isolates was > 1024 mcg/ml. The IC50 of dioxidin was 2.4+/-0.3 mM (low cytotoxicity). The results showed that the use of dioxidin as an antimicrobial for local application was advisable in the treatment of gramnegative bacterial infections provided adequate tissue concentrations were attained.

2004-01-01·Khirurgiia

[Prophylaxis of wound infection with immobilized antibacterial drugs].

Article

作者: Men'shikov, D D ; Bolenko, A V ; Titov, G P ; Kuprikov, S V

New drug ambipor that is an immobilized antibacterial agent with local prolonged therapeutic activity was developed for prophylaxis of wound suppuration. In ambipor A drugs gentamicin, dioxidin, kephzol and riphampicin are immobilazed, in iodopor - iodine. Experimental studies on 455 white rats showed that ambipor prevents suppuration, abscess formation around ligatures, improve regeneration and fibrillogenesis. In clinical practice ambipor A and iodopor were used in 562 patients. Rate of suppuration decreased from 11.7 to 2.3% compared with control group of patients.

100 项与 Dioxidin 相关的药物交易

登录后查看更多信息